The New England Journal of Medicine recently published a study evaluating sacituzumabe-govitecan-hziy. This drug, indicated for patients with metastatic triple-negative breast cancer (CMTNM), significantly improved progression-free survival and nearly doubled the overall survival of patients who had received at least two or more previous therapies for the disease, at least one after metastasis.
“Several advances have occurred in breast oncology, with treatment perspectives more focused on specific therapeutic targets and with a subsequent better tolerance profile, especially among luminal and HER-2 positive tumors”, says clinical oncologist Luciana Castro Garcia Landeiro, who is part of the NOB team, a clinic of the Oncoclínicas Group in Salvador (BA). “But in the scenario of triple-negative tumors, we still have a long way to go.”
Thaiana Aragão Santana, clinical oncologist at the Nucleus of Oncology of Sergipe (NOS), belonging to the Oncoclínicas Group, says that these tumors have a less favorable biology and more aggressive behavior than the other subtypes. She explains that, in Brazil, treatment with CMTN-targeted therapy is still limited to cases of metastatic disease: “For now, there are still no requests for approval of sacituzumabe-govitecan-hziy at Anvisa. The agency’s approved treatments include the immunotherapies pembrolizumab or atezolizumab in combination with chemotherapy for patients who express the PD-L1 protein. For patients with an identified BRCA mutation, a viable option is treatment with olaparib.”
Access our website and read the full article with all the details of this study.